OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients
The OTAC trial is assessing the safety and efficacy of hIVIG versus placebo in outpatients with COVID-19.
Asset / Drug
Drug and asset intelligence for COVID-19 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.